Formulation and Specifications: Tablets: 5 mg
Indications: Combined with an aromatase inhibitor for patients with locally advanced or metastatic breast cancer that is HR-positive, HER2-negative, postmenopausal, and has recurred or progressed with endocrine therapy.
Key points for rational dosing:
1. It should only be used in pathologically confirmed HR-positive, HER2-negative patients prior to treatment with cetapenem.
2. The starting dose of this product is 30 mg per dose, twice weekly, and the interval between doses should not be less than 3 days (e.g., Monday and Thursday, Tuesday and Friday, Wednesday and Saturday, etc.). Every 4 weeks is a dosing cycle. If the disease has not progressed or there are no intolerable adverse reactions, continuous dosing is recommended. Take 30 minutes after a meal.
3. Common adverse reactions are mainly hematological and therefore it is recommended that routine blood tests be performed prior to the use of this product and that the following indicators be met before starting the drug: absolute neutrophil values ≥ 1.5×109/L, platelets ≥ 75×109/L, and hemoglobin ≥ 90 g/L. Routine blood tests are required during the drug administration ( usually weekly). When the severity of hematologic adverse reactions reaches grade 3 or 4, the drug should be suspended. Treatment may be continued after two consecutive tests have been performed to confirm that the markers have returned to pre-dose levels. The dose for resumption is as follows: if the previous adverse reaction is grade 3, the original dose or the dose reduced to 20mg/dose can be used for resumption; if the previous adverse reaction is grade 4, the dose should be reduced to 20mg/dose for resumption.
4. At clinically relevant concentrations, cetapenem has no significant inhibitory or inducing effect on the major isoforms of human liver microsomal CYP450 enzymes.